CEO acquires 17,370 shares in Bulgarian drug maker Sopharma
Bulgarian drug maker Sopharma said on Tuesday that its CEO Ognyan Donev has acquired 17,370 shares in the company at a weighted average price per share of 3.3825 levs ($1.88/1.73 euro).Donev acquired the shares through deals on the Bulgarian Stock Exchange on September 30, Sopharma said in a bourse filing.The 17,370 shares are equal to a 0.0129% stake in Sopharma.Donev has been actively acquiring small packages of Sopharma shares since the start of September. Since then, Donev has made only one sale, of 3,620 shares.At the end of June, Donev held a stake of below 5% in Sopharma, according to the company's most recent interim financial statement.However, Ognyan Donev is indirectly the biggest shareholder in Sopharma, as he controls a 25.39% stake through his company Donev Investments Holding. Donev is also a major shareholder in Sopharma's second biggest shareholder - Telecomplect Invest. Telecomplect Invest controls 20.68% interest in Sopharma. As at 9:00 CET on Tuesday, Sopharma shares traded 0.59% lower at 3.35 levs on the Bulgarian Stock Exchange.